Top Active Pharmaceutical Ingredient Leaders Companies - Quadrant Report

Request Free Sample Report
Active Pharmaceutical Ingredients Market (Global) Company Evaluation Quadrant
Published on
Dec'2018
Pages
70
Code
360-PH 1262
Email
Share
Request Free Sample Report

An active pharmaceutical ingredient (API) is a drug or a combination of drugs used in the finished pharmaceutical product (FPP) intended for the diagnosis, treatment, or prevention of diseases.

The global active pharmaceutical ingredient market is estimated to reach USD 245.2 billion by 2024 from USD 182.2 billion in 2019, at a CAGR of 6.1% during the forecast period. The increasing incidence of chronic diseases, growing importance of generics, and the increasing uptake of biopharmaceuticals are some of the major factors driving the growth of the global APIs market. On the other hand, the unfavorable cexpected to restrain the growth of this market in the coming years.

Increasing incidence of chronic diseases to drive the growth of the Active Pharmaceutical Ingredients Market

This report identifies and benchmarks the Top Active Pharmaceutical Ingredient Companies such as Pfizer, Inc. (US), Novartis AG (Switzerland), Sanofi (France), Boehringer Ingelheim (Germany), Bristol-Myers Squibb (US), and evaluates them on the basis of business strategy excellence and strength of product portfolio within the Active Pharmaceutical Ingredients ecosystem, combining inputs from various industry experts, buyers, and vendors, and extensive secondary research including annual reports, company press releases, investor presentations, free and paid company databases. Top Active Pharmaceutical Ingredient Companies are rated and positioned on 2x2 matrix, called as ‘Company Evaluation Quadrant’, and identified as Visionary Leaders, Dynamic Differentiators, Innovators, or Emerging companies.


List of Top Active Pharmaceutical Ingredient Companies evaluated and profiled in the report:

  • ABBVIE INC.
  • ASTRAZENECA
  • BOEHRINGER INGELHEIM
  • BRISTOL-MYERS SQUIBB
  • ELI LILLY AND COMPANY
  • F. HOFFMANN-LA ROCHE
  • GLAXOSMITHKLINE PLC
  • MERCK & CO., INC.
  • NOVARTIS AG
  • PFIZER, INC.
  • SANOFI
  • TEVA PHARMACEUTICAL INDUSTRIES LTD.

Table of Contents

1 Introduction
   1.1 Market Definition

2 Market Overview
   2.1 Introduction
   2.2 Market Dynamics
          Figure 1 Active Pharmaceutical Ingredients Market: Drivers, Restraints, Opportunities, and Challenges
          2.2.1 Drivers
                    2.2.1.1 Increasing Incidence of Chronic Diseases
                    2.2.1.2 Technological Advancements in API Manufacturing
                    2.2.1.3 Growing Importance of Generics
                                 Table 1 Indicative List of Drugs Going Generic in 2018
                    2.2.1.4 Increasing Uptake of Biopharmaceuticals
                                 Table 2 Indicative List of Biologics That Gained Regulatory Approval in the US in 2017–2018
                    2.2.1.5 Growing Adoption of Artificial Intelligence-Based Tools for Drug Discovery
                    2.2.1.6 Adoption of Organ-On-Chip Models in Drug Development
                    2.2.1.7 Growing Focus on Precision Medicine
                    2.2.1.8 Growing Investments in Real-World Evidence By Pharmaceutical Companies
          2.2.2 Restraints
                     2.2.2.1 Unfavorable Drug Price Control Policies Across Various Countries
                     2.2.2.2 Increasing Penetration of Counterfeit Drugs
          2.2.3 Opportunities
                    2.2.3.1 Emerging Biosimilars Market
                                 Table 3 Indicative List of Biosimilars That Gained US Regulatory Approval in 2018
                    2.2.3.2 Highly Potent Active Pharmaceutical Ingredients
                    2.2.3.3 Emerging Markets
                    2.2.3.4 Emerging Technologies
          2.2.4 Challenges
                    2.2.4.1 Product Differentiation - A Major Concern for API Manufacturers
                    2.2.4.2 High Manufacturing Costs

3 Company Evaluation Quadrant
   3.1 Visionary Leaders
   3.2 Dynamic Differentiators
   3.3 Innovators
   3.4 Emerging Players
          Figure 2 Company Evaluation Quadrant of the Active Pharmaceutical Ingredients Market – Overall Market

4 Company Evaluation Quadrant – Startup/Sme
   4.1 Progressive Companies
   4.2 Starting Blocks
   4.3 Responsive Companies
   4.4 Dynamic Companies
          Figure 3 Company Evaluation Quadrant of the Active Pharmaceutical Ingredients Market – Start-Up/Sme

5 Competitive Landscape
   5.1 Overview
          Figure 4 Expansions—Key Growth Strategy Adopted By Market Players From 2015 to October 2018
   5.2 Market Player Ranking
          Figure 5 Active Pharmaceutical Ingredients Market Player Ranking, 2018
   5.3 Competitive Situation and Trends
         5.3.1 Product Launches
                   Table 4 Product Launches, 2016–2018
         5.3.2 Expansions
                   Table 5 Expansions, 2016–2018
         5.3.3 Acquisitions
                   Table 6 Acquisitions, 2015–2018
         5.3.4 Other Strategies
                   Table 7 Other Strategies, 2015–2018

6 Company Profiles
   6.1 Pfizer, Inc.
         6.1.1 Business Overview*
                   Figure 6 Pfizer, Inc.: Company Snapshot (2017)
         6.1.2 Products Offered*
         6.1.3 Recent Developments*
         6.1.4 MnM View*
         (*Above sections are present for all of below companies)
   6.2 Novartis AG
          Figure 7 Novartis AG: Company Snapshot (2017)
   6.3 Sanofi
          Figure 8 Sanofi: Company Snapshot (2017)
   6.4 Boehringer Ingelheim
          Figure 9 Boehringer Ingelheim: Company Snapshot (2017)
   6.5 Bristol-Myers Squibb
          Figure 10 Bristol-Myers Squibb: Company Snapshot (2017)
   6.6 Teva Pharmaceutical Industries Ltd.
          Figure 11 Teva Pharmaceutical Industries Ltd.: Company Snapshot (2017)
   6.7 Eli Lilly and Company
          Figure 12 Eli Lilly and Company: Company Snapshot (2017)
   6.8 GlaxoSmithKline PLC
          Figure 13 GlaxoSmithKline PLC: Company Snapshot (2017)
   6.9 Merck & Co., Inc.
          Figure 14 Merck & Co., Inc.: Company Snapshot (2017)
   6.10 AbbVie Inc.
            Figure 15 AbbVie Inc.: Company Snapshot (2017)
   6.11 F. Hoffmann-La Roche
            Figure 16 F. Hoffmann-La Roche: Company Snapshot (2017)
   6.12 AstraZeneca
            Figure 17 AstraZeneca: Company Snapshot (2017)

7 Appendix
   7.1 Methodology

This report identifies and benchmarks the Active Pharmaceutical Ingredient Leaders such as Pfizer, Inc. (US), Novartis AG (Switzerland), Sanofi (France), Boehringer Ingelheim (Germany), Bristol-Myers Squibb (US), and evaluates them on the basis of business strategy excellence and strength of product portfolio within the Active Pharmaceutical Ingredients ecosystem, combining inputs from various industry experts, buyers, and vendors, and extensive secondary research including annual reports, company press releases, investor presentations, free and paid company databases. Active Pharmaceutical Ingredient Leaders are rated and positioned on 2x2 matrix, called as ‘Company Evaluation Quadrant’, and identified as Visionary Leaders, Dynamic Differentiators, Innovators, or Emerging companies.

SAMPLES:

1450 USD
Licensing Options
Personalize Your Research Requirement
  • Updated version of this Quadrant
  • Different Company Evaluation Quadrant
  • 'Startup Only' Company Evaluation Quadrant
  • Region or Country specific evaluation
  • Application or Industry specific evaluation
  • ..Read More
Analyst Briefing & Inquiry
  • Submit a Briefing Request
  • Question about our published research
  • Request for evaluation of your organization for specific market
  • Request for re-evaluation of Company Evaluation Quadrant
  • ..Read More